DAY 29:
There was no noticeable difference between the Molnupiravir group and the placebo group in the amount of time it took for SARS-COV-2 to clear. (WMD: 1.72; 95% CI; [0.65, 4.53] p=0.27; I²=36%) (P-value for subgroup differences = 0.88). (Fig 3A).
Overall: The pooled analysis of 800mg molnipiravir and placebo deduce insignificant outcome in overall efficacy, (WMD: 1.90; 95% CI; [0.80, 4.53] p=0.14; I²=57%)